SCHEMBL23317336

SCHEMBL23317336

CCCC(C(=O)Nc1c(C)cc(F)cc1C)[PH](CC)(CC)CC

nearest known ligand 0.36

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PSEN1 P49768 3/20 0.34
PSEN2 P49810 3/20 0.34
APH1B Q8WW43 3/20 0.34
NCSTN Q92542 3/20 0.34
APH1A Q96BI3 3/20 0.34
PSENEN Q9NZ42 3/20 0.34
PYGL P06737 1/20 0.33
CYP2C9 P11712 1/20 0.33
TAS1R3 Q7RTX0 1/20 0.33
TAS1R1 Q7RTX1 1/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
HPGD P15428 3/20 0.32
ALDH1A1 P00352 3/20 0.32
LMNA P02545 1/20 0.32
NLRP3 Q96P20 1/20 0.31
GAA P10253 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23317545 0.89 PKM (0.34) CYP2C9HPGDALDH1A1LMNANLRP3
SCHEMBL23317396 0.89 LMNA (0.43) PYGLCYP2C9HPGDALDH1A1LMNA
SCHEMBL23317357 0.88 HPGD (0.34) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL23317558 0.87 PYGL (0.35) PSEN1PSEN2APH1BNCSTNAPH1A
SCHEMBL23317659 0.86 CA1 (0.37) PYGLCYP2C9TAS1R3TAS1R1CA1
SCHEMBL23317437 0.86 LMNA (0.39) CYP2C9ALDH1A1LMNAGAA
SCHEMBL23317582 0.84 KMT2A (0.36) TAS1R3TAS1R1HPGD
SCHEMBL23317208 0.83 ATM (0.43) CYP2C9ALDH1A1LMNANLRP3GAA
SCHEMBL23317560 0.83 ALDH1A1 (0.35) PYGLCYP2C9CA1CA2HPGD
SCHEMBL23317690 0.81 TSHR (0.35) HPGDALDH1A1LMNANLRP3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11701370-B2 Phosphonium ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-11701370-B2 Phosphonium ion channel blockers and methods for use Nocion Therapeutics, Inc. (US) 2023-07-18 US disclosed
US-20210128589-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE Nocion Therapeutics, Inc. 2021-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210128589-A1 PHOSPHONIUM ION CHANNEL BLOCKERS AND METHODS FOR USE TRPV1, TRPV5, TRPA1 PSEN1 341/4885PSEN2 528/4885APH1B 1149/4885
US-11701370-B2 Phosphonium ion channel blockers and methods for use TRPV1, TRPV5, TRPA1 PSEN1 341/4885PSEN2 528/4885APH1B 1149/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.